Evidence map›Paper›PMID 38197945›Full record

Observational studyEuropean journal of clinical pharmacology2024

Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.

Kristine Tveit, Monica Hermann, Roy M Nilsen, Susanna M Wallerstedt, Arvid Rongve, Espen Molden, Kristine Hole

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Kristine TveitDepartment of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Haugesund, Stord, Norway.ORCID http://orcid.org/0000-0002-6208-6562
Monica HermannDepartment of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Haugesund, Stord, Norway.ORCID http://orcid.org/0000-0002-8006-3591
Roy M NilsenDepartment of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Haugesund, Stord, Norway.ORCID http://orcid.org/0000-0002-6340-4593
Susanna M WallerstedtDepartment of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0001-7238-1680
Arvid RongveDepartment of Research and Innovation, Helse Fonna, Haugesund Hospital, Haugesund, Norway.ORCID http://orcid.org/0000-0002-0476-4134
Espen MoldenCenter for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-6190-2751
Kristine HoleCenter for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. kristine.hole@diakonsyk.no.ORCID http://orcid.org/0000-0001-7300-5329
Western Norway University of Applied Sciences · NODiakonhjemmet Hospital · NOPrivatsykehuset Haugesund · NOSahlgrenska University Hospital · SEUniversity of Oslo · NO

Funding

ERA PerMed ERAPERMED2021-357
6 · The paper itself

Abstract

purposeThe aim of this study was to examine the age of onset for increased dose-adjusted serum concentrations (C/D ratio) of common antidepressant drugs and to explore the potential association with sex and CYP2C19/CYP2D6 genotype.

methodsSerum concentrations and prescribed daily doses for citalopram, escitalopram, sertraline, venlafaxine and mirtazapine, and CYP genotypes, were obtained from a therapeutic drug monitoring (TDM) service. Segmented linear regression analysis was used to examine the relationship between age and antidepressant log C/D ratio in (i) all individuals, (ii) men and women, and (iii) CYP2D6/CYP2C19 normal metabolizers (NMs) and CYP2D6/CYP2C19 intermediate or poor metabolizers (IMs/PMs).

resultsA total of 34,777 individuals were included in the study; CYP genotype was available for 21.3%. An increase in C/D ratio started at 44‒55 years of age. Thereafter, the increase progressed more rapidly for citalopram and escitalopram than for venlafaxine and mirtazapine. A doubled C/D ratio was estimated to occur at 79 (citalopram), 81 (escitalopram), 86 (venlafaxine), and 90 years (mirtazapine). For sertraline, only modest changes in C/D ratio were observed. For escitalopram and venlafaxine, the observed increase in C/D ratio started earlier in women than in men. The results regarding CYP genotype were inconclusive.

conclusionThe age-related increase in C/D ratio starts in middle-aged adults and progresses up to more than twofold higher C/D ratio in the oldest old. Sertraline seems to be less prone to age-related changes in C/D ratio than the other antidepressants.

Indexed as

CitalopramSertralineAdultAged, 80 and overAge of OnsetAntidepressive AgentsCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6EscitalopramFemaleGenotypeHumansMaleMiddle AgedMirtazapineVenlafaxine HydrochlorideAntidepressive AgentsCitalopramCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6EscitalopramMirtazapineSertralineVenlafaxine HydrochlorideAgeAntidepressantPharmacokinetic variabilityTherapeutic drug monitoring

Identifiers

PMID38197945
PMCPMC10873233
OpenAlexW4390700160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.